Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

25.48 +0.23 (+0.91%)
Streaming Delayed Price Updated: 12:14 PM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Small Cap Biotechs Sagging But More Deals Are Likely to Perk Up the Market
Despite record highs in the Nasdaq recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. 
Via Talk Markets
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Where Veracyte Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Veracyte (NASDAQ: 
Via Benzinga
What 9 Analyst Ratings Have To Say About Veracyte
Within the last quarter, Veracyte (NASDAQ:VCYT) has observed the following... 
Via Benzinga
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
Expert Ratings For Veracyte
Within the last quarter, Veracyte (NASDAQ:VCYT) has observ... 
Via Benzinga
Vaccine Victory
Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson... 
Via Talk Markets
Topics Economy
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
From Veracyte, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers CASI Pharmaceuticals (NASDAQ:CASI 
Via Benzinga
Veracyte Completes Acquisition of HalioDx
From Veracyte
Via Business Wire
63 Biggest Movers From Friday
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Erytech Pharma (NASDAQ:ERYP) sha... 
Via Benzinga
41 Stocks Moving In Friday's Mid-Day Session
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares jumped 90.6% to $7.84 after the company said the FDA has granted its eryaspase fast track designation for the treatment of acute... 
Via Benzinga
Veracyte Announces Second Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?
Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position. 
Via The Motley Fool
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
From Veracyte, Inc.
Via Business Wire
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
From Veracyte, Inc.
Via Business Wire
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
From Veracyte, Inc.
Via Business Wire
Looking Into Veracyte's Return On Capital Employed
During Q1, Veracyte's (NASDAQ:VCYT) reported sales totaled $36.70 million. Despite a 462.62% in earnings, the company posted a loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Veracyte: Return On Capital Employed Insights
In Q1, Veracyte (NASDAQ:VCYT) posted sales of $36.70 million. Earnings were up 462.62%, but Veracyte still reported an overall loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
From Veracyte, Inc.
Via Business Wire
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.